48
Participants
Start Date
December 31, 2014
Primary Completion Date
November 30, 2016
TV005
TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10\^3 plaque forming units (PFUs) of each component (10\^3.3 PFUs/mL of rDEN1∆30, 10\^4.3 PFU/mL of rDEN2/4∆30(ME), 10\^3.3 PFU/mL of rDEN3∆30/31-7164 and 10\^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Placebo
The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
rDEN2∆30-7169
rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore
University of Vermont Vaccine Testing Center, Burlington
National Institute of Allergy and Infectious Diseases (NIAID)
NIH